UNSPSC 51183901: Farglitazar

This classification denotes an anti-diabetic agent with the molecular formula C34H30N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3433GY7132, chemically known as l-tyrosine, n-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl) but more generally known as farglitazar, which bears US NIH Compound Identifier 170364. The term FARGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46).

UNSPSC 51183901 Farglitazar, a Commodity code, captures pharmaceutical procurement by state and local government purchasing cooperatives and individual agencies acquiring generic multi-source pharmaceuticals and over-the-counter products through established wholesaler networks and direct manufacturer contracts. The work involves supplying specific National Drug Codes (NDCs) with detailed product specifications, manufacturing certifications, pricing structures, and supply-chain compliance documentation to state and local health systems, correctional facilities, and other public-sector healthcare operations. Issuers include state purchasing departments and multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant buyer consolidating demand across multiple state and local jurisdictions.

The Minnesota Department of Administration issued an RFP on January 20, 2026 (MMCAP S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. The procurement spans Minnesota and Oregon, with vendors required to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and submit pricing in fixed-price, net-price, or WAC-minus formats. Evaluation weighting emphasizes price competitiveness (75 percent), with secondary weight on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and administrative fee acceptance (5 percent). The contract term runs two years for new responders with optional extensions, effective July 1, 2026, and vendors must carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. MMCAP reserves sole, dual, or multi-award authority based on therapeutic and patient-safety considerations; no specific budget range is disclosed.